Abstract: A solid oxide fuel cell scatters MgO over a grain boundary of an LSGM which is a solid electrolyte layer. Ni components that diffuse from a fuel electrode formed on the other side of an LDC from the LSGM are trapped by the scattered MgO particles and are suppressed from diffusing towards an air electrode in the electrolyte layer.

Abstract: The present invention provides an aptamer that binds to IL-17 to inhibit binding of IL-17 and IL-17 receptor; a complex containing the aptamer and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery medium, drug and the like); a medicament containing the aptamer, or a complex containing the aptamer and a functional substance, a diagnosing drug and labeling agent and the like.

Abstract: On the other hand, the possibility of estimating the dopant ratio of a metal element to each ceria crystalline particle using integral-width or half-width obtained by XRD was considered as follows: an XRD peak is shifted depending on the dopant ratio of La to ceria; when La increases, an XRD peak is shifted to a lower angle; in XRD performed on a raw material obtained by mixing ceria crystalline particles having different dopant ratio, peaks corresponding to the respective dopant ratio exist close to each other; as a result, a peak width is widened; accordingly, the dopant ratio of a metal element to each ceria crystalline particles are supposed to vary when integral-width and half-width obtained by XRD are large. Thus, it was revealed for the first time that integral-width and half-width obtained by XRD indicate variations in dopant ratio. It should be noted that from the direct proportional relationship between the dopant ratio x and the integral-width for dopant ratio ranging from 0.35 to 0.

Abstract: Problem: To suppress the occurrence of damage to fuel cell units caused by oxidation shrinkage of fuel electrodes. Solution Means: The invention is a solid oxide fuel cell for generating electricity by reacting hydrogen and oxidant gas in individual fuel cell units, wherein the individual fuel cell units comprise a fuel electrode, an oxidant gas electrode, and a solid electrolyte erected between fuel electrode and oxidant gas electrode; the fuel electrode comprises a composite material containing nickel, and the solid oxide fuel cell prevents shrinkage due to oxidation of the fuel electrode by maintaining the fuel electrode in an oxygen-free atmosphere until the temperature of the fuel electrode has dropped to 350° C. after electrical generation is stopped.

Abstract: Provided are an aptamer having an inhibitory activity on FGF2; a complex containing an aptamer having a binding activity or an inhibitory activity on FGF2, and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery vehicle, or drug and the like); a medicament, diagnostic reagent or label containing an aptamer having a binding activity or an inhibitory activity on FGF2, or a complex containing said aptamer and a functional substance; and the like.

Abstract: Disclosed is a durable solid oxide fuel cell that is less likely to have a problem of a conventional solid oxide fuel cell that an air electrode containing a peroviskite oxide, when exposed to a reducing atmosphere, is separated at the stop of operation, especially shutdown. The solid oxide fuel cell includes an air electrode that is obtained by firing a compact containing a perovskite oxide and sulfur element. The content of the sulfur element in the air electrode as fresh after firing or before the start of power generation is in the range of 50 ppm to 3,000 ppm. The separation of the air electrode is effectively suppressed at the shutdown operation.

Abstract: A solid oxide fuel cell scatters MgO over a grain boundary of an LSGM which is a solid electrolyte layer. Ni components that diffuse from a fuel electrode formed on the other side of an LDC from the LSGM are trapped by the scattered MgO particles and are suppressed from diffusing towards an air electrode in the electrolyte layer.

Abstract: The invention provides an aptamer possessing an inhibitory activity against IL-17, as well as a complex comprising an aptamer possessing a binding activity or inhibitory activity against IL-17 and a functional substance (for example, affinity substances, substances for labeling, enzymes, drug delivery vehicles, drugs and the like). The invention also provides a pharmaceutical drug, cell migration inhibitor, diagnostic reagent, detection probe, carrier, labeling agent, and the like comprising the aforementioned aptamer or complex, and methods of detecting and purifying IL-17 by using the aforementioned aptamer or complex.

Abstract: Provided are an aptamer having an inhibitory activity on FGF2; a complex containing an aptamer having a binding activity or an inhibitory activity on FGF2, and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery vehicle, or drug and the like); a medicament, diagnostic reagent or label containing an aptamer having a binding activity or an inhibitory activity on FGF2, or a complex containing said aptamer and a functional substance; and the like.

Abstract: In one embodiment, a method is disclosed for manufacturing a device including forming a film on an object of processing using sputtering. The method can form a first film of a first sputtered particle on the object of processing at a first position. The first sputtered particle travels in a direction intersecting a major surface of a sputtering target. The object of processing and the sputtering target do not overlap as viewed in plan at the first position. In addition, the method can form a second film of a second sputtered particle on the first film at a second position. The second sputtered particle travels in a direction substantially orthogonal to the major surface of the sputtering target. The object of processing and the sputtering target at least partially overlap as viewed in plan at the second position. The second sputtered particle is screened in the case where the object of processing not having the first film formed on the object of processing is at the second position.

Abstract: The invention provides an aptamer possessing an inhibitory activity against IL-17, as well as a complex comprising an aptamer possessing a binding activity or inhibitory activity against IL-17 and a functional substance (for example, affinity substances, substances for labeling, enzymes, drug delivery vehicles, drugs and the like). The invention also provides a pharmaceutical drug, cell migration inhibitor, diagnostic reagent, detection probe, carrier, labeling agent, and the like comprising the aforementioned aptamer or complex, and methods of detecting and purifying IL-17 by using the aforementioned aptamer or complex.

Abstract: In a method of manufacturing a thin-film magnetic device having a magnetic film provided with uniaxial magnetic anisotropy, the magnetic film, which is formed on a Si wafer, is patterned, before it is heat-treated in a magnetic field, in such a manner that the length of the magnetic film in a direction parallel to that of the magnetic field is greater than the length of the magnetic film in a direction perpendicular thereto. The magnetic film is divided into band-like magnetic films, and the band-like magnetic films are heat-treated in the magnetic field and each provided with uniaxial magnetic anisotropy. The band-like magnetic films are patterned and each divided again into magnetic films of a chip size. Thus, a crack or a blister can be prevented from occurring on the magnetic film, and the magnetic characteristics of the magnetic film can be prevented from deteriorating.